Kirkland & Ellis advised Thoma Bravo on Bluesight’s acquisition of Medacist, a pioneer in drug diversion monitoring, which will further enhance Bluesight's drug diversion prevention offerings. Bluesight's acquisition of Medacist combines two innovators in drug diversion analytics and medication management solutions that together will serve more than 2,000 hospitals across North America. Financial terms of the transaction were not disclosed. Read Thoma Bravo’s press release The Kirkland team was led by corporate partners John Kaercher and Andrew Walker and associates Michael Fiedorowicz and Oscar Leija with assistance from corporate partner Bradley Reed; debt finance partner Fred Lim and associates David Love and Tina He; tax partners Adam Kool and Kevin Coenen and associates Natalie Kannan; technology & intellectual property transactions partners Aaron Lorber and Kevin Jacobsen; executive compensation partner Jake Ebers and associate Tom Kotlowski; employee benefits partner Robert Zitko and associate Nate Linger; employment & labor partner Sydney Jones and associate Jaime Wamble; and healthcare partner Anthony Del Rio and associate Olivia Seraphim. Related: Kirkland Advises Thoma Bravo on Controlling Investment in Bluesight